Postoperative concurrent chemoradiotherapy with paclitaxel/carboplatin chemotherapy in patients with high risk early stage cervical cancer.

Postoperative concurrent chemoradiotherapy with paclitaxel/carboplatin chemotherapy in patients with high risk early stage cervical cancer. - Postoperative CCRT using paclitaxel/carboplatin in patients with high risk early stage cervical cancer.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017231

Enrollment

Registered

2015-04-22

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uterine cervical cancer

Interventions

Concurrent weekly carboplatin and paclitaxel combined with adjuvant radiotherapy

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Early-stage cervical cancer patients with positive pelvic lymph nodes.

Exclusion criteria

Exclusion criteria: Early-stage cervical cancer patients without pelvic lymph nodes metastasis.

Design outcomes

Primary

Measure	Time frame
The maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of weekly paclitaxel/carboplatin chemoradiotherapy in early stage cervix cancer.	—

Secondary

Measure	Time frame
The efficacy of postoperative paclitaxel/carboplatin chemoradiotherapy in early stage cervix cancer.	—

Countries

Japan

Contacts

Public ContactSeiji Mabuchi

Osaka University Hospital Dept of Obstetrics and Gynecology.

smabuchi@gyne.med.osaka-u.ac.jp06-6879-3351

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026